Scibase Holding
0.331 SEK -7.8%35 investors are following this company
SciBase Holding is a medical technology company. The Group specializes in the management of cancer diagnostics, mainly focused on the treatment and detection of various melanomas. The company has developed an electric handheld probe that analyzes the measurement signal to detect specific changes in the body's skin tissue. The head office is located in Stockholm.
P/E (24e)
-1.36
EV/EBIT (adj.) (24e)
-1.11
P/B (24e)
2.56
Dividend yield-% (24e)
-
Target price
0.35 SEK
Recommendation
Reduce
Updated
18.4.2024
First North Stockholm
SCIB
Daily low / high price
0.326 / 0.358
SEK
Market cap
51.56M SEK
Turnover
43.16K SEK
Volume
122K
Business risk
Valuation risk
Current
Previous
Latest research
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
Antti Luiro
Head of Nordic ER Development, Analyst
Financial calendar
Extraordinary general meeting
13.05.2024
Interim report
31.05.2024
General meeting
13.06.2024
Interim report
21.08.2024
Interim report
12.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Gell Group | 11.0 % | 11.0 % |
Avanza Pension | 9.7 % | 9.7 % |
Premium
This content is for our Premium customers only.
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 9.5 | 11.7 | 17.9 | 23.2 | 31.9 | 50.4 | 81.5 | 129.3 |
growth-% | 2.6 % | 23.2 % | 52.6 % | 29.9 % | 37.3 % | 57.9 % | 61.6 % | 58.7 % |
EBITDA | -32.2 | -38.7 | -42.8 | -50.6 | -52.7 | -44.0 | -26.3 | 3.0 |
EBIT (adj.) | -34.8 | -41.6 | -46.4 | -53.9 | -56.1 | -46.9 | -29.5 | -0.4 |
EBIT | -34.8 | -41.6 | -46.4 | -53.9 | -56.1 | -46.9 | -29.5 | -0.4 |
Profit before taxes | -35.0 | -41.8 | -43.2 | -55.6 | -56.7 | -47.4 | -30.0 | -0.9 |
Net income | -35.0 | -41.8 | -43.2 | -55.6 | -56.7 | -47.4 | -30.0 | -0.9 |
EPS (adj.) | -1.12 | -0.67 | -0.63 | -0.51 | -0.24 | -0.20 | -0.13 | -0.00 |
growth-% | ||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -337.7 % | -329.6 % | -239.1 % | -217.5 % | -165.0 % | -87.2 % | -32.3 % | 2.4 % |
EBIT-% (adj.) | -365.2 % | -354.8 % | -259.5 % | -232.0 % | -175.9 % | -93.1 % | -36.2 % | -0.3 % |
EBIT-% | -365.2 % | -354.8 % | -259.5 % | -232.0 % | -175.9 % | -93.1 % | -36.2 % | -0.3 % |
ROE | -88.7 % | -71.0 % | -89.9 % | -162.8 % | -154.9 % | -736.9 % | 92.9 % | 1.9 % |
ROI | -88.2 % | -70.7 % | -96.7 % | -158.0 % | -153.4 % | -151.8 % | -73.4 % | -0.7 % |
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (SEK) | 4.48 | 5.36 | 3.71 | 0.83 | 0.33 | 0.33 | 0.33 | 0.33 |
Shares | 54.8 | 68.5 | 68.5 | 119.8 | 233.7 | 233.7 | 233.7 | 233.7 |
Market cap | 245.6 | 366.9 | 253.9 | 99.9 | 77.3 | 77.3 | 77.3 | 77.3 |
Enterprise value | 204.2 | 301.3 | 235.1 | 65.8 | 62.4 | 116.2 | 157.0 | 174.8 |
EV/S | 21.4 | 25.7 | 13.1 | 2.8 | 2.0 | 2.3 | 1.9 | 1.4 |
EV/EBITDA | - | - | - | - | - | - | - | 57.5 |
EV/EBIT (adj.) | - | - | - | - | - | - | - | - |
EV/EBIT | - | - | - | - | - | - | - | - |
P/E (adj.) | - | - | - | - | - | - | - | - |
P/E | - | - | - | - | - | - | - | - |
P/B | 5.2 | 5.2 | 10.1 | 2.3 | 2.6 | - | - | - |
P/S | 25.8 | 31.3 | 14.2 | 4.3 | 2.4 | 1.5 | 0.9 | 0.6 |
Dividend yield | ||||||||
Equity ratio | 79.1 % | 82.8 % | 50.6 % | 66.9 % | 51.7 % | -24.3 % | -44.7 % | -30.7 % |
Gearing ratio | -88.4 % | -92.7 % | -74.6 % | -79.2 % | -49.7 % | -225.1 % | -168.5 % | -202.1 % |
Quarter data
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 5.1 | 5.1 | 7.2 | 5.8 | 23.2 | 6.8 | 7.3 | 9.8 | 8.1 |
EBITDA | -10.0 | -12.8 | -12.0 | -15.7 | -50.6 | -12.8 | -13.2 | -12.7 | -14.0 |
EBIT | -10.8 | -13.8 | -12.7 | -16.6 | -53.9 | -13.7 | -14.1 | -13.6 | -14.8 |
Profit before taxes | -10.9 | -11.4 | -12.8 | -20.5 | -55.6 | -13.8 | -14.2 | -13.7 | -15.0 |
Net income | -10.9 | -11.4 | -12.8 | -20.5 | -55.6 | -13.8 | -14.2 | -13.7 | -15.0 |
ShowingAll content types
SciBase supports clinicians during US Skin Cancer Awareness Month
SciBase enters UAE through a sales and distribution partnership
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools